Table 1.

The study population characteristics at baseline and follow-up in the Renal Iohexol-Clearance Survey Follow-Up Study

CharacteristicsBaseline MeasurementsFollow-Up MeasurementsP Valuea
All MeasurementsIncluded in Follow-Up
N (%)1590 (100)1296 (81)1296 (81)
Men, n (%)778 (49)641 (49)641 (49)
Age, yr58.0 (3.8)58.0 (3.9)63.6 (4.0)<0.001
Height, cm170.7 (8.7)170.8 (8.6)170.6 (8.6)<0.001
Body weight, kg79.5 (14.3)79.4 (13.9)79.2 (14.2)0.25
Body mass index, kg/m227.2 (4.0)27.1 (3.8)27.1 (4.0)0.59
TNFR2, pg/ml2670 (652)2661 (624)
hsCRP, mg/L1.19 (0.64–2.19)1.17 (0.64–2.13)
Systolic BP, mmHg129.4 (17.5)129.1 (17.4)130.5 (16.9)<0.001
Diastolic BP, mmHg83.4 (9.8)83.3 (9.8)81.9 (9.3)<0.001
Fasting glucose, mg/dl95.8 (8.7)95.7 (8.5)98.7 (10.1)<0.001
Hemoglobin A1c, %5.54 (0.33)5.5 (0.33)5.61 (0.32)<0.001
LDL cholesterol, mg/dl141.5 (33.2)141.6 (32.9)138.2 (34.6)<0.001
HDL cholesterol, mg/dl59.31 (16.25)59.46 (16.08)63.11 (17.92)<0.001
Fasting triglycerides, mg/dl88.5 (70.8–132.8)88.5 (70.8–123.9)88.5 (70.8–115.1)0.12
UACR, mg/g2.04 (0.88–4.78)1.92 (0.88–4.60)3.00 (0.88–5.13)<0.001
ACEi, n (%)28 (1.8)26 (2.0)48 (3.7)<0.001
ARB, n (%)131 (8.2)104 (8.0)200 (15.4)<0.001
NSAIDs, n (%)37 (2.3)30 (2.3)77 (5.9)<0.001
Current smoker, n (%)322 (20)241 (19)172 (13)<0.001
Alcohol consumption, n (%)432 (27)365 (29)431 (33)<0.001
Absolute mGFR, ml/min103.8 (20.0)103.6 (20)98.3 (19.8)<0.001
mGFR, ml/min per 1.73 m293.8 (14.3)93.7 (14.2)88.9 (14.4)<0.001
eGFR by CKD-EPI equation, ml/min per 1.73 m2
 eGFRcre94.8 (9.6)94.8 (9.3)88.1 (10.5)<0.001
 eGFRcys105.4 (12.3)105.7 (12.1)98.8 (14.1)<0.001
 eGFRcrecys103.0 (11.4)103.1 (11.2)95.7 (12.7)<0.001
  • Estimates are given as mean (SD), median (interquartile range), or n (%). TNFR2, soluble TNF receptor 2; hsCRP, high-sensitivity C-reactive protein; UACR, urinary albumin-creatinine ratio; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; mGFR, measured GFR; CKD-EPI; Chronic Kidney Disease Epidemiology Collaboration; eGFRcre, eGFR on the basis of creatinine; eGFRcys, eGFR on the basis of cystatin C; eGFRcrecys, eGFR on the basis of creatinine and cystatin C.

  • a P value for change between baseline and follow-up.